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We thank Dr Veinot for his excellent comments concerning embolization and fibroelastomas. The association between fibroelastomas and embolic stroke is indeed controversial. The diagnosis of ischemic stroke from left-sided papillary fibroelastomas is usually made by exclusion. In a recent study, Yee and colleagues 1 reported on 15 patients with papillary fibroelastomas and found 5 patients (33%) who had ischemic strokes with no other etiologic explanation. Furthermore, thrombus is occasionally superimposed on papillary fibroelastomas. 2 It may have been responsible for the stroke in the patient whom we reported, although no fibrin or thrombus was observed on pathology. Anticoagulation is a viable alternative to surgical excision of the tumor, particularly when there are contraindications to surgery. In 1 case report, no recurrence of transient ischemic attack occurred in 3 years after excision of a left-sided papillary fibroelastoma. Follow-up data on patients who underwent surgical excision are rare, and we are unaware of any follow-up studies on patients treated with anticoagulation alone. The best method of management of papillary fibroelastomas, the secondmost-common cardiac tumor, 3 
Is Atherosclerosis a No NO State?
To the Editor: A recent article in Circulation by Lüscher's group (Oemar et al) 1 has reported that in tissue derived from human atherosclerotic lesions, endothelial NO synthase (eNOS) protein expression as well as NO release are markedly reduced. They then suggested that these reductions are involved in the progression of atherosclerosis.
We would like to provide further support for their contention that an altered NO system is involved in human atherosclerosis. In a series of articles, our group has established that patients with Bartter syndrome or Gitelman syndrome, syndromes that show a peculiar picture of vascular hyporeactivity characterized by normotension/hypotension in the presence of elevated levels of pressor agents (eg, angiotensin II, norepinephrine, and aldosterone), have an anomalous calcium-dependent signaling system 2 and an upregulation of the NO system. 3, 4 In particular, this upregulation is characterized by increased ecNOS mRNA levels as well as increased and correlated urinary excretions of NO metabolites (NO 2 Ϫ /NO 3 Ϫ ) and cGMP, the second messenger of NO. In these same patients, we have also demonstrated a reduced susceptibility of their LDL to oxidation, 5 as shown by reduced production of thiobarbituric acid-reactive substances as well as volatile lipid peroxidation products such as pentanal and hexanal. In addition, the lag phase of conjugated diene formation in the Bartter and Gitelman patients was strongly correlated with urinary excretion of NO 2 Ϫ /NO 3 Ϫ . This suggests that NO serves as an antioxidant and therefore as a protective mechanism against oxidative stress, endothelial dysfunction, and atherosclerosis. Our results in Bartter and Gitelman patients therefore represent the mirror image of the results reported by Oemar et al 1 
Response
We greatly appreciate the comments by Davis and Calò related to our recently published article. 1 The syndrome the authors studied, namely, Bartter and Gitelman patients, is of great interest in this context. The fact that NO serves as an antioxidant and therefore a protective mechanism against oxidative stress is also in line with our recently published "Current Perspective" in Circulation. 2 It is of great interest that nature has provided a mirror picture of atherosclerosis in these patients and that this mirror picture provides further support for the protective role of NO against atherosclerosis and related cardiovascular conditions. 
Thomas F. Lü scher, MD

Direct Antigen Presentation and Chronic Rejection
To the Editor: I read with interest the article by Hornick et al. 1 They conclude that direct antigen presentation (donor MHC presented by donor antigen-presenting cells) is an unlikely mechanism to explain the accelerated coronary disease (CAD) that develops after cardiac transplantation. I have concerns regarding these data and conclusions.
First and foremost, the data are limited to 10 allograft recipients studied at wide time disparities, with the majority of recipients being at least 4 years past transplantation. Although the development of CAD is progressive, disease occurring later after transplantation is difficult to distinguish from traditional atherosclerosis. Furthermore, most of the alloimmune "action" occurs within the first year after transplantation. Several studies have demonstrated that those patients who develop CAD early have by far the worst prognosis. Only 2 patients were studied in this time frame. Second, only patients with CAD were studied without a control group. The appropriate comparison (assuming consistent time periods) would be those with and without CAD, not donor-specific versus third party. It is important to also point out that 5 of the 10 patients had precursor frequencies to donor-specific antigens similar to third-party antigens, with patients later after transplantation tending to have less aggressive responses.
Third, the progressive loss of donor-specific alloreactivity in stable allograft recipients, based on precursor frequency or MLR, is not a new finding. 2, 3 More importantly, Rabinowich et al 4 demonstrated that an augmented MLR correlated with both acute and chronic rejection in lung transplant recipients using BAL cells as responders and donor spleen cells as stimulators. Our own data 5 are somewhat more intriguing because they showed a dichotomy between the standard MLR (using donor lymphocytes as stimulators) and lymphocyte proliferation when donor endothelial cells were used. Although a hyporesponsive effect developed over the first year when the standard MLR was used, recipient lymphocyte reactivity actually increased in response to donor-specific endothelial cells. These data raise the possibility that different costimulatory signals occur in this lymphocyte-endothelial interaction compared with an MLR, or alternatively, this response is less well inhibited by immunosuppression. A subsequent study in 52 cardiac allograft recipients correlated the intensity of this response serially to the development of angiographic coronary disease by 1 year after transplantation. 6 On the basis of the above, I would have to conclude that the question of direct antigen presentation as a mechanism for chronic rejection is still an open one. 
Jeffrey D. Hosenpud, MD
Response
Dr Hosenpud makes several important observations with which we agree. First, we accept that we studied only a small number of patients and that the findings we reported need to be confirmed in a larger series. We are currently accumulating prospective data in renal transplant recipients in order to extend these observations to chronic rejection in another context. Second, we agree that the direct alloresponse is maximally active during the first few weeks and months after transplantation, when the highly immunogenic donor passenger leukocytes are present. Third, we are well aware of the correlation between early transplant coronary artery disease (TxCAD) and acute rejection 1 ; this implies that the direct alloresponse sets in motion a cycle of events that manifest as TxCAD at a later time point. Fourth, not only are we familiar with previous reports of emerging donorspecific hyporesponsiveness in transplant patients, but we have described this observation ourselves in renal transplant recipients 2, 3 However, this is the first description of donor-specific hyporesponsiveness in cardiac patients with established and progressive TxCAD, which is thought to be the manifestation of chronic cardiac allograft rejection.
Having identified where we agree with Dr Hosenpud, we would like to highlight where we disagree. First, as stated above, our study makes a novel observation in patients with the clinical manifestation of chronic cardiac allograft rejection. Second, we dispute the importance of a control group without TxCAD. The thrust of our findings is that a continuing strong antidonor direct alloresponse is unlikely to be responsible for continuing TxCAD. This conclusion would be uninfluenced by the study of CAD-free patients, whatever pattern of reactivity they displayed. Finally, Dr Hosenpud's observation that hyporesponsiveness against donor peripheral blood mononuclear cells (PBMCs) may occur while reactivity against donor endothelial cells (ECs) is preserved is potentially interesting. However, until a mechanism can be identified to explain this dichotomy, it remains a somewhat puzzling phenomenon. Indeed, in our own studies, alloreactive T cells primed against allogeneic PBMCs respond to ECs expressing the same alloantigens when bystander costimulation is provided, suggesting the conservation of alloantigenic epitopes, although accessory molecular interactions may differ.
Further definition of the nature of the T-cell alloresponse that drives chronic allograft rejection is clearly crucially important. Our recent data support the possibility that the indirect rather than the direct alloresponse is of greater significance. In a recent issue of Circulation, Javaheri et al 1 demonstrated that sleep-disordered breathing (SDB), including central sleep apnea (CSA) and periodic breathing (eg, Cheyne-Strokes respiration), is extremely common in patients with stable heart failure and that atrial fibrillation, ventricular arrhythmia, and low left ventricular function are associated with sleep apnea in these patients. Because the reversal of SDB by nasal continuous positive pressures and oxygen may lead to improvements in markers of cardiovascular outcome in selected patients with congestive heart failure (CHF), all cardiologists should pay attention to the recent study. However, the mechanisms of SDB in patients with CHF were not extensively discussed in the article. The same authors recently proposed that low PaCO 2 resulted in ventilatory instability and central apnea during sleep. 2 In the previous study, the values of PaCO 2 were 37Ϯ5 and 39Ϯ4 mm Hg in patients with SDB and those without SDB, respectively. Although the differences in resting PaCO 2 in arterial blood gas between awake patients with SDB and those without SDB were very small, experimental human study suggested that central apnea could be induced by lowering PaCO 2 1 to 3 mm Hg below resting PaCO 2 while patients were awake. 3 In addition, instability in the ventilatory control system might be involved in periodic breathing. 4 The higher prevalence of CSA in patients with SDB is at least in part explained by ventilatory instability as indicated by low PaCO 2 . Wilcox and coworkers 5 also revealed that CHF patients with CSA had decreased awake end-tidal CO 2 tension (4.1Ϯ0.5 kPa), increased ventilatory response to CO 2 , and eucapnic hypoxic responses in the normal range, but that CHF patients with obstructive sleep apnea had a normal awake end-tidal CO 2 tension and normal ventilatory response to CO 2 . These data indicated that ventilatory instability and augmented chemosensitivity to hypercapnia were important factors in the pathophysiology of CSA in patients with CHF. In addition, it is known that oxygen effectively reduces CSA but not obstructive sleep apnea in patients with CHF. This suggests that oxygen supplementation therapy may be beneficial for both cardiac function and SDB in patients with CHF. Considered together, the assessment of arterial blood gases is particularly important for both detection and treatment of CSA in patients with CHF.
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